• 1
    Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29 (Suppl. 1): 7481.
  • 2
    Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008; 48: 14862.
  • 3
    Houghton M, Weiner A, Han J, et al. Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease. Hepatology 1991; 14: 3818.
  • 4
    Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 7916.
  • 5
    Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007; 5: 45363.
  • 6
    Villano SA, Vlahov D, Nelson KE, et al. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999; 29: 90814.
  • 7
    Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003; 125: 808.
  • 8
    Orland JR, Wright TL, Cooper S. Acute hepatitis C. Hepatology 2001; 33: 3217.
  • 9
    Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 67784.
  • 10
    Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52: 83344.
  • 11
    Zeuzem S, Berg T, Moeller B, et al. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat 2009; 16: 7590.
  • 12
    Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358: 95865.
  • 13
    Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 97582.
  • 14
    McHutchison JG, Lawitz EJ, IDEAL Study Team et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 58093.
  • 15
    Colin C, Lanoir D, HEPATITIS Group et al. Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature. J Viral Hepat 2001; 8: 8795.
  • 16
    Sookoian S, Castaño G. Evaluation of a third generation anti-HCV assay in predicting viremia in patients with positive HCV antibodies. Ann Hepatol 2002; 1: 17982.
  • 17
    Alborino F, Burighel A, Tiller FW, van Helden J, et al. Multicenter evaluation of a fully automated third-generation anti-HCV antibody screening test with excellent sensitivity and specificity. Med Microbiol Immunol 24 September 2010 [Epub ahead of print] DOI: DOI: 10.1007/s00430-010-0171-0.
  • 18
    Uyttendaele S, Claeys H, Mertens W, et al. Evaluation of third-generation screening and confirmatory assays for HCV antibodies. Vox Sang 1994; 66: 1229.
  • 19
    Nolte FS, Fried MW, Shiffman ML, et al. Prospective multicenter clinical evaluation of AMPLICOR and COBAS AMPLICOR hepatitis C virus tests. J Clin Microbiol 2001; 39: 400512.
  • 20
    Lee SC, Antony A, Lee N, et al. Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics. J Clin Microbiol 2000; 38: 41719.
  • 21
    Gerken G, Rothaar T, Rumi MG, et al. Performance of the COBAS AMPLICOR HCV MONITOR test, version 2.0, an automated reverse transcription-PCR quantitative system for hepatitis C virus load determination. J Clin Microbiol 2000; 38: 22104.
  • 22
    Ross RS, Viazov S, Sarr S, et al. Quantitation of hepatitis C virus RNA by third generation branched DNA-based signal amplification assay. J Virol Methods 2002; 101: 15968.
  • 23
    Sarrazin C, Teuber G, Kokka R, et al. Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays. Hepatology 2000; 32: 81823.
  • 24
    Leckie G, Schneider G, Abravaya K, et al. Performance attributes of the LCx HCV RNA quantitative assay. J Virol Methods 2004; 115: 20715.
  • 25
    Hendricks DA, Friesenhahn M, Tanimoto L, et al. Multicenter evaluation of the VERSANT HCV RNA qualitative assay for detection of hepatitis C virus RNA. J Clin Microbiol 2003; 41: 6516.
  • 26
    Vermehren J, Kau A, Gärtner BC, et al. Differences between two real-time PCR-based hepatitis C virus (HCV) assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and one signal amplification assay (Versant HCV RNA 3.0) for RNA detection and quantification. J Clin Microbiol 2008; 46: 38891.
  • 27
    Schutten M, Fries E, Burghoorn-Maas C, et al. Evaluation of the analytical performance of the new Abbott RealTime RT-PCRs for the quantitative detection of HCV and HIV-1 RNA. J Clin Virol 2007; 40: 99104.
  • 28
    Sarrazin C, Dragan A, Gärtner BC, et al. Evaluation of an automated, highly sensitive, real-time PCR-based assay (COBAS Ampliprep/COBAS TaqMan) for quantification of HCV RNA. J Clin Virol 2008; 43: 1628.
  • 29
    Sizmann D, Boeck C, Boelter J, et al. Fully automated quantification of hepatitis C virus (HCV) RNA in human plasma and human serum by the COBAS AmpliPrep/COBAS TaqMan system. J Clin Virol 2007; 38: 32633.
  • 30
    Sarrazin C, Gärtner BC, Sizmann D, et al. Comparison of conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5. J Clin Microbiol 2006; 44: 72937.
  • 31
    Chevaliez S, Bouvier-Alias M, Brillet R, et al. Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. Hepatology 2007; 46: 2231.
  • 32
    Kolykhalov AA, Feinstone SM, Rice CM. Identification of a highly conserved sequence element at the 3′ terminus of hepatitis C virus genome RNA. J Virol 1996; 70: 336371.
  • 33
    Tanaka T, Kato N, Cho MJ, et al. Structure of the 3′ terminus of the hepatitis C virus genome. J Virol 1996; 70: 330712.
  • 34
    Simmonds P. Genetic diversity and evolution of hepatitis C virus – 15 years on. J Gen Virol 2004; 85: 317388.
  • 35
    Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42: 96273.
  • 36
    Germer JJ, Vandenameele JN, Mitchell PS, et al. Automated sample preparation for the TRUGENE HIV-1 genotyping kit using the MagNA pure LC instrument. Diagn Microbiol Infect Dis 2004; 49: 5961.
  • 37
    Stuyver L, Wyseur A, van Arnhem W, et al. Second-generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol 1996; 34: 225966.
  • 38
    Stuyver L, Wyseur A, van Arnhem W, et al. Hepatitis C virus genotyping by means of 5′-UR/core line probe assays and molecular analysis of untypeable samples. Virus Res 1995; 38: 13757.
  • 39
    Zheng X, Pang M, Chan A, et al. Direct comparison of hepatitis C virus genotypes tested by INNO-LiPA HCV II and TRUGENE HCV genotyping methods. J Clin Virol 2003; 28: 2146.
  • 40
    Lange CM, Sarrazin C, Zeuzem S. Review article: specifically targeted anti-viral therapy for hepatitis C − a new era in therapy. Aliment Pharmacol Ther 2010; 32: 1428.
  • 41
    Chevaliez S, Bouvier-Alias M, Brillet R, et al. Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. PLoS One 2009; 4: e8209.
  • 42
    Maheshwari A, Ray S, Thuluvath PJ. Acute hepatitis C. Lancet 2008; 372: 32132.
  • 43
    Farci P, Alter HJ, Wong D, et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 1991; 325: 98104.
  • 44
    Quiroga JA, Campillo ML, Catillo I, et al. IgM antibody to hepatitis C virus in acute and chronic hepatitis C. Hepatology 1991; 14: 3843.
  • 45
    Martinot-Peignoux M, Stern C, Ripault M-P, et al. Twelve weeks post-treatment follow-up is as relevant as 24 weeks to determine the SVR in patients with HCV receiving PEG-IFN and ribavirin. Hepatology 2010; 51: 11226.
  • 46
    Sarrazin C, Berg T, Ross RS, et al. Prophylaxis, diagnosis and therapy of hepatitis c virus (HCV) infection: the German guidelines on the management of HCV infection. Z Gastroenterol 2010; 48: 289351.
  • 47
    Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 97582.
  • 48
    Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alpha-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 64552.
  • 49
    Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alpha-2a (40 KD)/ribavirin. J Hepatol 2005; 43: 42533.
  • 50
    Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alpha-2a plus ribavirin. Gastroenterology 2006; 130: 108697.
  • 51
    Berg T, Sarrazin C, Herrmann E, et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003; 37: 6009.
  • 52
    Sánchez-Tapias JM, Diago M, TeraViC-4 Study Group et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131: 45160.
  • 53
    Sarrazin C, Schwendy S, Möller B, et al. COMPLETELY Individualized treatment durations (24, 30, 36, 42, 48, 60 OR 72 Weeks) with peginterferon-alfa-2B and ribavirin in hcv genotype 1-infected patients (INDIV-2 STUDY). J Hepatol 2010; 52 (Suppl. 1): S256.
  • 54
    Afdhal N, Levine R, Brown R, et al. Colchicine versus PEG-Interferon alpha 2b long term therapy: results of the 4 year copilot trial. J Hepatol 2008; 48(Suppl. 2): S4.
  • 55
    Di Bisceglie AM, Shiffman ML, Everson GT, et al. HALT-C Trial Investigators. Prolonged therapy of advanced chronic hepatitis C with low dose peginterferon. N Engl J Med 2008; 359: 242941.
  • 56
    Bruix J, Poynard T, Colombo M, et al. Pegintron maintenance therapy in cirrhotic (Metavir F4) HCV patients, who failed to respond to interferon/ribavirin (IR) therapy: final results of the EPIC3 cirrhosis maintenance trial. J Hepatol 2009; 50: A49.
  • 57
    Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alpha-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44: 97103.
  • 58
    Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43: 95460.
  • 59
    Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alpha-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135: 4518.
  • 60
    Hadziyannis SJ, Sette Jr H, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 34655.
  • 61
    Nasta P, Gatti F, Puoti M, et al. Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alpha-2a. AIDS 2008; 22: 85761.
  • 62
    Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008; 49: 63451.
  • 63
    Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology 2007; 46: 168894.
  • 64
    Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. Hepatology 2008; 47: 4350.
  • 65
    Ferenci P, Laferl H, Scherzer TM, et al. Customizing treatment with peginterferon alpha-2a (40KD) plus ribavirin in patients with HCV genotype 1 or 4 infection: interimresults of a prospective randomized trial. Hepatology 2006; 44: 336A.
  • 66
    Buti M, Lurie Y, SUCCESS Study Investigators et al. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Hepatology 2010; 52: 12017.
  • 67
    Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alpha-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357: 1243.
  • 68
    Dalgard O, Bjoro K, Hellum KB, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14weeks: a pilot study. Hepatology 2004; 40: 12605.
  • 69
    von Wagner M, Huber M, Berg T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129: 5227.
  • 70
    Mangia A, Santoro R, Minerva N, et al. Peginterferon alpha-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 260917.
  • 71
    Yu ML, Dai CY, Huang JF, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007; 56: 5539.
  • 72
    Dalgard O, Bjoro K, Ring-Larsen H, et al. Pegylated interferon alpha and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008; 47: 3542.
  • 73
    Diago M, Shiffman ML, Bronowicki JP, et al. Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin. Hepatology 2010; 51: 1897903.
  • 74
    Andriulli A, Dalgard O, Bjoro K, et al. Short-term treatment duration for HCV-2 and HCV-3 infected patients. Dig Liver Dis 2006; 38: 7418.
  • 75
    Mangia A, Ricci GL, Persico M, et al. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine v. interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C. J Viral Hepat 2005; 12: 2929.
  • 76
    Willems B, Hadziyannis SJ, Morgan TR, et al. Should treatment with peginterferon plus ribavirin be intesified in patients with genotype 2/3 without a rapid virological response? # 8. J Hepatol 2007; 46(Suppl. 1): S6.
  • 77
    Sarrazin C, Shiffman ML, Hadziyannis SJ, et al. Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy. J Hepatol 2010; 52: 8328.
  • 78
    Neumann AU, Pianko S, Zeuzem S, et al. Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naïve patients with genotype 1, chronic hepatitis C. J Hepatol 2009; 51: 218.
  • 79
    Martinot-Peignoux M, Maylin S, Moucari R, et al. Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin. Antivir Ther 2009; 14: 50111.
  • 80
    Mihm U, Herrmann E, Sarrazin C, Zeuzem S. Review article: predicting response in hepatitis C virus therapy. Aliment Pharmacol Ther 2006; 23: 104354.
  • 81
    Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399401.
  • 82
    Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus. Gastroenterology 2010; 139: 1209.
  • 83
    Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferonalpha and ribavirin therapy. Nat Genet 2009; 41: 11004.
  • 84
    Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferonalpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 11059.
  • 85
    Asselah T. Genetic polymorphism and response to treatment in chronic hepatitis C: the future of personalized medicine. J Hepatol 2010; 52: 4524.
  • 86
    Kotenko SV, Gallagher G, Baurin VV, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4: 6977.
  • 87
    Mangia A, Thompson AJ, Santoro R, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010; 139: 8217.